847 results match your criteria CNS Melanoma

Synthesis and Anti-Cancer Activity of New Pyrazolinyl-Indole Derivatives: Pharmacophoric Interactions and Docking Studies for Identifying New EGFR Inhibitors.

Int J Mol Sci 2022 Jun 11;23(12). Epub 2022 Jun 11.

Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Qassim 51452, Saudi Arabia.

Newly designed series of indole-containing pyrazole analogs, pyrazolinylindoles, were synthesized, and their structures were confirmed based on the spectral data of the H NMR, C NMR, and HR-MS analyses. Preliminary anti-cancer activity testings were carried out by the National Cancer Institute, United States of America (NCI, USA). Compounds HD02, HD05, and HD12 demonstrated remarkable cytotoxic activities against nine categories of cancer types based cell line panels which included leukemia, colon, breast, melanoma, lungs, renal, prostate, CNS, and ovarian cancer cell lines. Read More

View Article and Full-Text PDF

Central nervous system magnetic resonance imaging abnormalities and neurologic outcomes in pediatric patients with congenital nevi: A 10-year multi-institutional retrospective study.

J Am Acad Dermatol 2022 Jun 15. Epub 2022 Jun 15.

Department of Dermatology, Massachusetts General Hospital, Boston, MA; Dermatology Program, Department of Allergy and Immunology, Boston Children's Hospital, Boston, MA; Harvard Medical School, Boston, MA.

Background: High-risk congenital melanocytic nevi (CMN) are associated with abnormalities of the central nervous system, prompting MRI screening guidelines.

Objective: Describe MRI brain and spine abnormalities in children with CMN and report trends between nevus features, MRI findings, and neurologic outcomes.

Methods: Retrospective review of individuals aged ≤ 18 years with an MRI of brain and/or spine and at least 1 dermatologist-diagnosed CMN. Read More

View Article and Full-Text PDF

Microenvironmental landscape of human melanoma brain metastases in response to immune checkpoint inhibition.

Cancer Immunol Res 2022 Jun 15. Epub 2022 Jun 15.

Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.

Melanoma-derived brain metastases (MBM) represent an unmet clinical need because central nervous system (CNS) progression is frequently an end-stage of the disease. Immune checkpoint inhibitors (ICI) provide a clinical opportunity against MBM; however, the MBM tumor microenvironment (TME) has not been fully elucidated in the context of ICI. To dissect unique elements of the MBM TME and correlates of MBM response to ICI, we collected 32 fresh MBM and performed single-cell RNA sequencing of the MBM TME and T-cell receptor clonotyping on T cells from MBM and matched blood and extracranial lesions. Read More

View Article and Full-Text PDF

Prevalence and Clinicopathologic Features of Canine Metastatic Melanoma Involving the Central Nervous System: A Retrospective Analysis and Comparative Review.

Front Oncol 2022 27;12:868004. Epub 2022 May 27.

Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, Davis, CA, United States.

Background: Central nervous system (CNS) involvement is the leading cause of death in malignant melanoma. Rodent models, while vital to mechanistic investigation, have had limited success identifying effective therapies for melanoma brain metastases. The companion dog with melanoma is a promising complementary model for developmental therapeutic investigation, as these tumors occur in an immunologically outbred host that has shared environmental exposures with humans. Read More

View Article and Full-Text PDF

Integrative RNA profiling of TBEV-infected neurons and astrocytes reveals potential pathogenic effectors.

Comput Struct Biotechnol J 2022 30;20:2759-2777. Epub 2022 May 30.

Faculty of Science, University of South Bohemia in České Budějovice, Branišovská 1760, České Budějovice 370 05, Czech Republic.

Tick-borne encephalitis virus (TBEV), the most medically relevant tick-transmitted flavivirus in Eurasia, targets the host central nervous system and frequently causes severe encephalitis. The severity of TBEV-induced neuropathogenesis is highly cell-type specific and the exact mechanism responsible for such differences has not been fully described yet. Thus, we performed a comprehensive analysis of alterations in host poly-(A)/miRNA/lncRNA expression upon TBEV infection in human primary neurons (high cytopathic effect) and astrocytes (low cytopathic effect). Read More

View Article and Full-Text PDF

Factors associated with preoperative and postoperative seizures in patients undergoing resection of brain metastases.

J Neurosurg 2022 Apr 29:1-8. Epub 2022 Apr 29.

1Department of Neurological Surgery and.

Objective: Epileptic seizures are a common and potentially devastating complication of metastatic brain tumors. Although tumor-related seizures have been described in previous case series, most studies have focused on primary brain tumors and have not differentiated between different types of cerebral metastases. The authors analyzed a large surgical cohort of patients with brain metastases to examine risk factors associated with preoperative and postoperative seizures and to better understand the seizure risk factors of metastatic brain tumors. Read More

View Article and Full-Text PDF

Clinical Reasoning: A 67-Year-Old Woman With Abdominal Pain, Constipation, and Urinary Retention.

Neurology 2022 May 6. Epub 2022 May 6.

University of Vermont Larner College of Medicine.

Meningeal melanocytomas are an extremely rare, pigmented tumors of the central nervous system (CNS). They generally carry a favorable prognosis, although recurrence and transformation into the more aggressive malignant melanoma has been reported. We present a case of a patient who reported constipation and abdominal pain around the umbilicus, which progressed into cord compression with lower extremity weakness and gait instability. Read More

View Article and Full-Text PDF

Associations between TERT Promoter Mutations and Survival in Superficial Spreading and Nodular Melanomas in a Large Prospective Patient Cohort.

J Invest Dermatol 2022 Apr 22. Epub 2022 Apr 22.

The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, NYU Langone Health, New York, New York, USA; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA; Department of Pathology, NYU Grossman School of Medicine, NYU Langone Health, New York, New York, USA. Electronic address:

Survival outcomes in melanoma and their association with mutations in the telomerase reverse transcriptase gene TERT promoter remain uncertain. In addition, few studies have examined whether these associations are affected by a nearby common germline polymorphism or vary on the basis of melanoma histopathological subtype. We analyzed 408 primary tumors from a prospective melanoma cohort for somatic TERT and TERT mutations, the germline polymorphism rs2853669, and BRAF and NRAS mutations. Read More

View Article and Full-Text PDF

The AIM2 inflammasome is activated in astrocytes during the late phase of EAE.

JCI Insight 2022 Apr 22;7(8). Epub 2022 Apr 22.

Department of Immunology, Duke University School of Medicine, Durham, North Carolina, USA.

Inflammasomes are a class of innate immune signaling platforms that activate in response to an array of cellular damage and pathogens. Inflammasomes promote inflammation under many circumstances to enhance immunity against pathogens and inflammatory responses through their effector cytokines, IL-1β and IL-18. Multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis (EAE), are autoimmune conditions influenced by inflammasomes. Read More

View Article and Full-Text PDF

Does pigmentation, hemosiderin and blood effect visible 5-ALA fluorescence in cerebral melanoma metastasis?

Photodiagnosis Photodyn Ther 2022 Apr 14;39:102864. Epub 2022 Apr 14.

Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Comprehensive Cancer Center - Central Nervous System Tumours Unit (CCC-CNS), Medical University Vienna (MUW), Vienna, Austria.

Introduction: The clinical impact of 5-aminolevulinic acid (5-ALA) fluorescence during resection of brain metastases is not yet clear.. Recent data demonstrated significantly lower incidence of visible fluorescence in cerebral melanoma metastases (CMM) compared to other brain metastases (BM). Read More

View Article and Full-Text PDF

Histopathological Analysis of Central Nervous System Metastases: Six Years of Data From a Tertiary Center.

Cureus 2022 Feb 12;14(2):e22151. Epub 2022 Feb 12.

Pathology, Health Sciences University Adana City Training and Research Hospital, Adana, TUR.

Introduction: The most common cause of neurological symptoms in patients with systemic malignant tumors is central nervous system (CNS) metastases, and CNS metastases are one of the important causes of morbidity and mortality in these patients. The most common metastatic tumors to the CNS are lung, breast, malignant melanoma, genitourinary, and gastrointestinal tumors. We aimed to analyze our data on patients with CNS metastases in our department, which belongs to a large archive in the field of neuropathology. Read More

View Article and Full-Text PDF
February 2022

Malignant Melanoma of the Brainstem: A Unicorn Not a Popcorn.

Neurol India 2022 Jan-Feb;70(1):340-344

Department of Neurosurgery, All India Institute of Medical Sciences, New-Delhi, India.

Background: Primary intracranial malignant melanomas (PIMMs) are uncommon lesions of the central nervous system. Brainstem involvement is of rare occurrence.

Methods And Material: A 33-year-old male presented with the chief complaints of progressively increasing headache, visual disturbances, and diplopia from the last 6 months. Read More

View Article and Full-Text PDF

SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021).

Clin Transl Oncol 2022 Apr 8;24(4):703-711. Epub 2022 Mar 8.

Medical Oncology Department, Hospital Universitario, 12 de Octubre, Madrid, Spain.

Central nervous system (CNS) dissemination is a severe complication in cancer and a leading cause of cancer-related mortality. Brain metastases (BMs) are the most common types of malignant intracranial tumors and are reported in approximately 25% of patients with metastatic cancers. The recent increase in incidence of BMs is due to several factors including better diagnostic assessments and the development of improved systemic therapies that have lower activity on the CNS. Read More

View Article and Full-Text PDF

Primary intracranial melanoma, amelanotic variant: Case report.

Neurocirugia (Astur : Engl Ed) 2022 Mar 2. Epub 2022 Mar 2.

Servicio de Neurocirugía, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Instituto de investigación Sanitaria de Aragón (IISA), Spain.

Primary brain melanoma is a very rare tumour (only 0.07% of primary CNS neoplasms) which usually shows with abundant melanin content; whereas hypo/melanotic variants have been scarcely described. We introduce the case of a female patient with headache, left brachial paresis and frontallobar syndrome. Read More

View Article and Full-Text PDF

The systemic management of central nervous system metastases and leptomeningeal disease from advanced lung, melanoma, and breast cancer with molecular drivers: An Australian perspective.

Asia Pac J Clin Oncol 2022 Mar 3. Epub 2022 Mar 3.

Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, Melbourne, Victoria, Australia.

The advent of systemic therapies with high intracranial efficacy in recent years is changing the therapeutic paradigm and renewing interest in the management of central nervous system (CNS) and leptomeningeal metastases from solid organ tumors. CNS metastases have traditionally heralded a dismal prognosis with median survival of 3-10 months, and were primarily treated with local therapeutic modalities, such as surgery or radiation therapy. Although these modalities still have a role in the management of CNS disease, newer agents, such as small molecule tyrosine kinase inhibitors and immune-checkpoint inhibitors, are now paving the way as an alternative therapeutic option for those with oligometastatic or low-volume intracranial disease, potentially eliminating or delaying the need for local treatment modalities in this setting. Read More

View Article and Full-Text PDF

Neurological signs, symptoms and MRI abnormalities in patients with congenital melanocytic naevi and evaluation of routine MRI-screening: systematic review and meta-analysis.

Orphanet J Rare Dis 2022 03 2;17(1):95. Epub 2022 Mar 2.

Department of Dermatology, Amsterdam Public Health, Amsterdam University Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

Background: A congenital melanocytic naevus (CMN) is a rare skin condition that can be associated with abnormalities of the central nervous system (CNS). These anomalies can sometimes cause severe complications, and rarely death. Adequate information about aetiology and management is therefore crucial. Read More

View Article and Full-Text PDF

Economic and health care resource utilization burden of central nervous system metastases in patients with metastatic melanoma.

J Manag Care Spec Pharm 2022 Mar;28(3):342-353

Genentech, Inc., South San Francisco, CA.

In patients with metastatic melanoma, central nervous system (CNS) involvement is associated with poor prognosis, increased costs, and higher health care resource utilization (HCRU); however, previous cost-estimate studies were conducted before widespread use of targeted therapies and immunotherapies. To estimate costs and HCRU in patients with metastatic melanoma with and without CNS metastases in the current treatment era following introduction of targeted therapies and immunotherapies. This real-world retrospective cohort study used data from the IQVIA PharMetrics Plus claims database to estimate and compare costs and HCRU in patients with metastatic melanoma by presence or absence of CNS metastases between January 2011 and June 2019. Read More

View Article and Full-Text PDF

Factors associated with progression and mortality among patients undergoing stereotactic radiosurgery for intracranial metastasis: results from a national real-world registry.

J Neurosurg 2022 Jan 14:1-14. Epub 2022 Jan 14.

14Department of Neurological Surgery, University of Virginia Health System, Charlottesville, Virginia.

Objective: Stereotactic radiosurgery (SRS) has been increasingly employed in recent years to treat intracranial metastatic lesions. However, there is still a need for optimization of treatment paradigms to provide better local control and prevent progressive intracranial disease. In the current study, the authors utilized a national collaborative registry to investigate the outcomes of patients with intracranial metastatic disease who underwent SRS and to determine factors associated with lesion treatment response, overall progression, and mortality. Read More

View Article and Full-Text PDF
January 2022

[Primary diffuse meningeal melanomatosis: a literature review and a case report].

Arkh Patol 2022 ;84(1):27-32

Prof. A.L. Polenov Russian Research Institute of Neurosurgery - Branch V.A. Almazov National Medical Research Center of the Ministry of Health of Russia, St. Petersburg, Russia.

Primary melanocytic tumors of the central nervous system (CNS) are extremely rare and account for only 1% of all melanomas and 0.05% of primary brain tumors. In case of diffusely invasive lesions of the pia mater with a tumor of melanocytic origin (without signs of extracranial metastases), the tumors are classified as primary diffuse meningeal melanomatosis (PDMM). Read More

View Article and Full-Text PDF
February 2022

Challenges and Advances in Diagnosis and Treatment of Leptomeningeal Disease (LMD).

Front Oncol 2021 12;11:800053. Epub 2022 Jan 12.

Department of Melanoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX, United States.

Leptomeningeal disease (LMD) is a devastating category of CNS metastasis with a very poor prognosis and limited treatment options. With maximal aggressive therapy, survival times remain short and, without treatment, prognosis is measured in weeks. Both LMD diagnosis and treatment are challenging topics within neuro-oncology. Read More

View Article and Full-Text PDF
January 2022

Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma.

Front Immunol 2021 11;12:810388. Epub 2022 Jan 11.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

With the increasing promise of long-term survival with immune checkpoint blockade (ICB) therapies, particularly for patients with advanced melanoma, clinicians and investigators are driven to identify prognostic and predictive factors that may help to identify individuals who are likely to experience durable benefit. Several ICB combinations are being actively developed to expand the armamentarium of treatments for patients who may not achieve long-term responses to ICB single therapies alone. Thus, negative predictive markers are also of great interest. Read More

View Article and Full-Text PDF

Surgery for brain metastases-impact of the extent of resection.

Acta Neurochir (Wien) 2022 Jan 26. Epub 2022 Jan 26.

Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Background: Surgical resection of brain metastases improves symptoms and survival in selected patients. The benefit of gross total resection is disputed, as most patients are believed to succumb from their non-CNS tumor burden. We investigated the association between overall survival and residual tumor after surgery for single brain metastases. Read More

View Article and Full-Text PDF
January 2022

Fever of unknown origin and incidence of cancer.

Clin Infect Dis 2022 Jan 25. Epub 2022 Jan 25.

Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.

Background: Diagnostic tools for determining causes of fever of unknown origin (FUO) have improved over time. We examined if cancer incidence among these patients changed over a 20-year period.

Methods: Population-based cohort study using nationwide Danish registries. Read More

View Article and Full-Text PDF
January 2022

Case Report: Differential Genomics and Evolution of a Meningeal Melanoma Treated With Ipilimumab and Nivolumab.

Front Oncol 2021 5;11:691017. Epub 2022 Jan 5.

Radiology Department, Clinica del County/Resonancia Magnética de Colombia, Bogotá, Colombia.

Primary melanocytic tumors of the CNS are extremely rare conditions, encompassing different disease processes including meningeal melanoma and meningeal melanocytosis. Its incidence range between 3-5%, with approximately 0.005 cases per 100,000 people. Read More

View Article and Full-Text PDF
January 2022

A Case of Metastatic CNS Melanoma of Unknown Primary Presenting with Seizures.

Case Rep Med 2022 6;2022:3099750. Epub 2022 Jan 6.

Medical Specialists of the Palm Beaches Neurology, JFK Medical Center, Atlantis, FL, USA.

Seizures are a common occurrence. The goal of evaluating a seizure is to identify the etiology and to determine the likelihood of recurrence as well as guide management. We present a unique presentation of a 47-year-old female that presented with late onset seizures admitted due to status epilepticus. Read More

View Article and Full-Text PDF
January 2022

Updates on Molecular Targeted Therapies for Intraparenchymal CNS Metastases.

Cancers (Basel) 2021 Dec 21;14(1). Epub 2021 Dec 21.

Malnati Brain Tumor Institute at the Robert H. Lurie Comprehensive Cancer Center, Department of Neurology at the Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.

Central nervous system (CNS) metastases can occur in a high percentage of systemic cancer patients and is a major cause of morbidity and mortality in these patients. Almost any histology can find its way to the brain, but lung, breast, and melanoma are the most common pathologies seen in the CNS from metastatic disease. Identification of many key targets in the tumorigenesis pathway has been crucial to the development of a number of drugs that have demonstrated successful penetration of the blood-brain, blood-cerebrospinal fluid, and blood-tumor barriers. Read More

View Article and Full-Text PDF
December 2021

Structural optimization of 4-(imidazol-5-yl)pyridine derivatives affords broad-spectrum anticancer agents with selective B-RAF/p38α kinase inhibitory activity: Synthesis, in vitro assays and in silico study.

Eur J Pharm Sci 2022 Apr 4;171:106115. Epub 2022 Jan 4.

Center of Biomaterials, Korea Institute of Science & Technology (KIST School), Seoul, Seongbuk-gu, 02792, Republic of Korea; University of Science & Technology (UST), Daejeon, Yuseong-gu, 34113, Republic of Korea. Electronic address:

In the current article, we introduce design of a new series of 4-(imidazol-5-yl)pyridines with improved anticancer activity and selective B-RAF/p38α kinase inhibitory activity. Based on a previous work, a group of structural modifications were applied affording the new potential antiproliferative agents. Towards extensive biological assessment of the target compounds, an in vitro anticancer assay was conducted over NCI 60-cancer cell lines panel representing blood, lung, colon, CNS, skin, ovary, renal, prostate, and breast cancers. Read More

View Article and Full-Text PDF

Quantitative cerebrospinal fluid circulating tumor cells are a potential biomarker of response for proton craniospinal irradiation for leptomeningeal metastasis.

Neurooncol Adv 2021 Jan-Dec;3(1):vdab181. Epub 2021 Dec 4.

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Background: Leptomeningeal metastasis (LM) involves cerebrospinal fluid (CSF) seeding of tumor cells. Proton craniospinal irradiation (pCSI) is potentially effective for solid tumor LM. We evaluated whether circulating tumor cells (CTCs) in the CSF (CTC), blood (CTC), and neuroimaging correlate with outcomes after pCSI for LM. Read More

View Article and Full-Text PDF
December 2021

Immunotherapy for Neuro-oncology.

Adv Exp Med Biol 2021 ;1342:233-258

Department of Neuro-Oncology, MD Anderson Cancer Center, Houston, TX, USA.

Immunotherapy has changed the landscape of treatment of many solid and hematological malignancies and is at the forefront of cancer breakthroughs. Several circumstances unique to the central nervous system (CNS) such as limited space for an inflammatory response, difficulties with repeated sampling, corticosteroid use for management of cerebral edema, and immunosuppressive mechanisms within the tumor and brain parenchyma have posed challenges in clinical development of immunotherapy for intracranial tumors. Nonetheless, the success of immunotherapy in brain metastases (BMs) from solid cancers such as melanoma and non-small cell lung cancer (NSCLC) proves that the CNS is not an immune-privileged organ and is capable of initiating and regulating immune responses that lead to tumor control. Read More

View Article and Full-Text PDF
January 2022

Comment on "Fatal GNAQ-mutated CNS melanoma in an adolescent with nevus of Ota".

Pediatr Dermatol 2021 11;38(6):1608-1609

Harvard Medical School, Boston, Massachusetts, USA.

View Article and Full-Text PDF
November 2021